Century Therapeutics (NASDAQ:IPSC) Cut to Sell at Wall Street Zen

Century Therapeutics (NASDAQ:IPSC) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Century Therapeutics in a research report on Saturday, September 27th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Century Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $3.75.

Century Therapeutics Stock Up 3.2%

Century Therapeutics stock opened at $0.51 on Friday. Century Therapeutics has a 12-month low of $0.34 and a 12-month high of $1.83. The business’s 50-day moving average price is $0.52 and its two-hundred day moving average price is $0.54. The stock has a market cap of $44.34 million, a PE ratio of -1.77 and a beta of 1.78.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Thursday, August 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.38). Century Therapeutics had a negative return on equity of 11.53% and a negative net margin of 19.10%. As a group, analysts expect that Century Therapeutics will post -1.61 earnings per share for the current year.

Hedge Funds Weigh In On Century Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in Century Therapeutics in the second quarter valued at approximately $248,000. Raymond James Financial Inc. bought a new stake in shares of Century Therapeutics during the second quarter valued at approximately $51,000. Qube Research & Technologies Ltd bought a new stake in shares of Century Therapeutics during the second quarter valued at approximately $38,000. Marshall Wace LLP bought a new stake in shares of Century Therapeutics during the second quarter valued at approximately $78,000. Finally, Prudential Financial Inc. bought a new stake in shares of Century Therapeutics during the second quarter valued at approximately $25,000. 50.20% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.